Suchergebnisse - "Kanate, Abraham S."

PubPharm (79)

1

Updated Indications for Immune Effector Cell Therapy : 2023 Guidelines from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2023

von Kanate, A. | Majhail, N. | DeFilipp, Z. | +9

2

Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas

enthalten in: Transplantation and cellular therapy | 2023

von Mussetti, A. | Kanate, A. | Wang, T. | +20

3

Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

enthalten in: Journal of cancer research and clinical oncology | 2023

von Topp, M. | Eradat, H. | Florschütz, A. | +12

4

Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas

enthalten in: Transplantation and cellular therapy | 28 February 2023

von Mussetti, A. | Kanate, A. | Wang, T. | +20

5

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma

enthalten in: Clinical pharmacology in drug development | 2022

von Forero-Torres, A. | Chandler, J. | Iyer, S. | +6

6

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

enthalten in: Journal of cancer research and clinical oncology | 2022

von Topp, M. | Eradat, H. | Florschütz, A. | +12

7

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

enthalten in: Journal of cancer research and clinical oncology | 2022

von Topp, M. | Eradat, H. | Florschütz, A. | +12

8

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

9

Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B‐Cell Non‐Hodgkin's Lymphoma

enthalten in: Clinical Pharmacology in Drug Development | 2022

von Forero‐Torres, A. | Chandler, J. | Iyer, S. | +6

10

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European Journal of Haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

1
2
3
4
5
6
7
8
Nächster »
[8]